Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Sciences Linea COVID-19 Selective Genomic Surveillance Mutation Panel

Applied DNA Sciences has launched the Linea COVID-19 Selective Genomic Surveillance Mutation Panel (SGS Panel) to enhance the utility of next-generation sequencing resources in the US to better track SARS-CoV-2 variants of concern at the local, state, and federal levels. The research-use-only SGS Panel uses a matrix of proprietary qPCR assays that target salient mutations that characterize relevant identified variants of concern to narrow the selection of positive samples worth subjecting to NGS analysis, the Stony Brook, New York-based company said. Applied DNA Sciences will offer the SGS panel in 100 reaction kits. It is also planning to offer additional RUO services that include NGS sequencing of entire viral genomes. The firm is targeting the sequencing of 100 SARS-CoV-2 viromes per day with a capacity for twice that number.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.